BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473-1485. [PMID: 22849511 DOI: 10.1517/14712598.2012.711308] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Trifirò G, Marcianò I, Ingrasciotta Y. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opinion on Biological Therapy 2017;18:309-15. [DOI: 10.1080/14712598.2018.1410134] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
2 Santi D, Simoni M. Biosimilar recombinant follicle stimulating hormones in infertility treatment. Expert Opinion on Biological Therapy 2014;14:1399-409. [DOI: 10.1517/14712598.2014.925872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
3 Ebbers HC, Crow SA, Vulto AG, Schellekens H. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012;30:1186-90. [DOI: 10.1038/nbt.2438] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
4 Bellinvia S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. Expert Opin Drug Discov 2020;15:1283-9. [PMID: 32717155 DOI: 10.1080/17460441.2020.1796627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Cornes P, Aapro M. The Impact of Biosimilars in Supportive Care in Cancer. European Oncology & Haematology 2018;14:20. [DOI: 10.17925/eoh.2018.14.1.20] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 D'Amore C, Da Cas R, Rossi M, Traversa G. Switching Between Epoetins: A Practice in Support of Biosimilar Use. BioDrugs 2016;30:27-32. [PMID: 26728875 DOI: 10.1007/s40259-015-0155-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
7 Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them? Curr Rheumatol Rep 2016;18. [DOI: 10.1007/s11926-016-0601-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
8 Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? BioDrugs 2020;34:723-32. [PMID: 32990892 DOI: 10.1007/s40259-020-00446-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Cappello B, Moja L, Figueras A, Magrini N. The "Square Box": Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines. Front Pharmacol 2020;11:578000. [PMID: 33071791 DOI: 10.3389/fphar.2020.578000] [Reference Citation Analysis]
10 Covic A, Abraham I. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. Int Urol Nephrol 2015;47:1529-39. [DOI: 10.1007/s11255-015-1042-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Review of Clinical Pharmacology 2015;8:649-59. [DOI: 10.1586/17512433.2015.1071188] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
12 Schneider CK, Weise M. [Regulatory aspects of biosimilars. Myths and facts]. Z Rheumatol 2015;74:695-700. [PMID: 26385104 DOI: 10.1007/s00393-014-1489-6] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Goldsmith D, Dellanna F, Schiestl M, Krendyukov A, Combe C. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience? Clin Drug Investig 2018;38:481-90. [PMID: 29500617 DOI: 10.1007/s40261-018-0637-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
14 Mellstedt H. Anti-neoplastic biosimilars—the same rules as for cytotoxic generics cannot be applied. Annals of Oncology 2013;24:v23-8. [DOI: 10.1093/annonc/mdt325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
15 Schreiber S, Panés J, Kwon B, Hong S, Peyrin-biroulet L. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. Expert Review of Gastroenterology & Hepatology 2015;9:5-15. [DOI: 10.1586/17474124.2015.1091304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Müller-ladner U, Hong S, Oh C, Taylor P. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. Expert Review of Clinical Immunology 2015;11:5-14. [DOI: 10.1586/1744666x.2015.1090310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
17 Mansell K, Bhimji H, Eurich D, Mansell H. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. BMC Health Serv Res 2019;19:827. [PMID: 31718624 DOI: 10.1186/s12913-019-4680-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. The Lancet Oncology 2016;17:e502-9. [DOI: 10.1016/s1470-2045(16)30374-6] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
19 Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: Review of current applications, obstacles, and their future in medicine. World J Clin Cases 2018; 6(8): 161-166 [PMID: 30148143 DOI: 10.12998/wjcc.v6.i8.161] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
20 Mkinsi O, Lefkir-tafiani S, Srairi HS, Kochbati S, El Dershaby YM, El Azhari MM, Midjek SA, Ladjouze-rezig A. Regulatory Perspectives on Biopharmaceuticals for Chronic Inflammatory Diseases in North Africa: A Narrative Review. TORJ 2019;13:72-84. [DOI: 10.2174/1874312901913010072] [Reference Citation Analysis]
21 Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10:981-983. [PMID: 24961712 DOI: 10.1586/1744666x.2014.932690] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Marin JG, Leung M, Lo C, Tsao NW, Martinusen DJ. Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review. Can J Kidney Health Dis 2014;1:34. [PMID: 25780623 DOI: 10.1186/s40697-014-0034-5] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
23 Harsányi A, Csanádi M, Márky K, Vincziczki ÁZ, Kaló Z, Inotai A. Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Rev Pharmacoecon Outcomes Res 2020;20:653-9. [PMID: 31510811 DOI: 10.1080/14737167.2019.1667232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Blauvelt A, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, Skov L, Zachariae C, Young H, Prens E, Cohen A, van der Walt J, Wu JJ. Biosimilars for psoriasis: clinical studies to determine similarity. Br J Dermatol 2017;177:23-33. [PMID: 27639072 DOI: 10.1111/bjd.15067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
25 Krendyukov A, Schiestl M. Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies. Crit Rev Oncol Hematol 2019;:102785. [PMID: 31405784 DOI: 10.1016/j.critrevonc.2019.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs 2018;78:463-78. [PMID: 29500555 DOI: 10.1007/s40265-018-0881-y] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 33.7] [Reference Citation Analysis]
27 Inotai A, Prins CPJ, Csanádi M, Vitezic D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther 2017;17:915-26. [PMID: 28650704 DOI: 10.1080/14712598.2017.1341486] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
28 Wiland P, Batko B, Brzosko M, Kucharz EJ, Samborski W, Świerkot J, Więsik-Szewczyk E, Feldman J. Biosimilar switching - current state of knowledge. Reumatologia 2018;56:234-42. [PMID: 30237628 DOI: 10.5114/reum.2018.77975] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
29 Goncalves J, Matos de Brito P, Batista A, Feio J, Machado F, Aperta J, Ascensão I, Pires V, Oliveira C, Armandina Pontes R, Alcobia A, Paulo Cruz J, Lampreia Guerreiro S, Farinha H, Margarida Freitas A, Caetano M, Almeida P, Costa B, Oliveira C, Campos C, Madureira B, Cavaco M, Catarino H; other members presented at APFH meeting of biosimilar positioning on behalf of Portuguese Association of Hospital Pharmacists. Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies. J Clin Pharm Ther 2017;42:239-43. [PMID: 27859438 DOI: 10.1111/jcpt.12477] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. Biomed Res Int 2018;2018:9597362. [PMID: 29546072 DOI: 10.1155/2018/9597362] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
31 Casadevall N, Felix T, Strober BE, Warnock DG. Similar names for similar biologics. BioDrugs 2014;28:439-44. [PMID: 25001080 DOI: 10.1007/s40259-014-0099-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
32 Dylst P, Vulto A, Simoens S. Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study. PharmacoEconomics 2014;32:681-91. [DOI: 10.1007/s40273-014-0163-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
33 Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. Clin Pharmacol Ther 2020;108:734-55. [PMID: 32236956 DOI: 10.1002/cpt.1836] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
34 Serra López-matencio JM, Morell Baladrón A, Castañeda S. Fármacos biosimilares: un nuevo escenario en las terapias biológicas. Reumatología Clínica 2017;13:287-93. [DOI: 10.1016/j.reuma.2016.05.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
35 Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A Multidisciplinary Perspective. Clin Ther. 2016;38:1238-1249. [PMID: 26988243 DOI: 10.1016/j.clinthera.2016.02.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
36 Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of Biosimilars: A European Perspective. BioDrugs 2017;31:83-91. [PMID: 28120313 DOI: 10.1007/s40259-017-0210-0] [Cited by in Crossref: 102] [Cited by in F6Publishing: 82] [Article Influence: 20.4] [Reference Citation Analysis]
37 Hlavaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. European Journal of Gastroenterology & Hepatology 2014;26:581-7. [DOI: 10.1097/meg.0000000000000098] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
38 Uifălean A, Ilieş M, Nicoară R, Rus LM, Hegheş SC, Iuga CA. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars. Pharmaceutics 2018;10:E168. [PMID: 30257528 DOI: 10.3390/pharmaceutics10040168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
39 Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. The Lancet Oncology 2016;17:e31-8. [DOI: 10.1016/s1470-2045(15)00381-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
40 Aapro M, Krendyukov A, Schiestl M, Gascón P. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained. BioDrugs 2018;32:129-35. [PMID: 29417431 DOI: 10.1007/s40259-018-0262-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
41 Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67. [PMID: 24790409 DOI: 10.2147/BTT.S27578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Belleudi V, Trotta F, Addis A, Ingrasciotta Y, Ientile V, Tari M, Gini R, Pastorello M, Scondotto S, Cananzi P, Traversa G, Davoli M, Trifirò G; Italian Biosimilar Network (ItaBioNet). Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. Drug Saf 2019;42:1437-47. [PMID: 31228010 DOI: 10.1007/s40264-019-00845-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
43 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Jongsma MME, Vulto A, de Ridder L. The use of biosimilars in paediatric inflammatory bowel disease. Curr Opin Pediatr 2017;29:560-5. [PMID: 28692448 DOI: 10.1097/MOP.0000000000000529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Gispen-de Wied CC, Leufkens HG. From molecule to market access: Drug regulatory science as an upcoming discipline. European Journal of Pharmacology 2013;719:9-15. [DOI: 10.1016/j.ejphar.2013.07.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
46 Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm 2013;70:2004-17. [PMID: 24173009 DOI: 10.2146/ajhp130119] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
47 Abad Hernández MÁ, Andreu JL, Caracuel Ruiz MÁ, Belmonte Serrano MÁ, Díaz-gonzález F, Moreno Muelas JV. Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. Reumatología Clínica 2015;11:269-78. [DOI: 10.1016/j.reuma.2015.03.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
48 O'Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol 2019;75:1-11. [PMID: 30187103 DOI: 10.1007/s00228-018-2542-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
49 Wilson P, Wood C. Biosimilar ESAs: a comparative review. J Ren Care 2015;41:53-61. [PMID: 25348203 DOI: 10.1111/jorc.12099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
50 Sala V, Cnudde SJ, Murabito A, Massarotti A, Hirsch E, Ghigo A. Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. Eur J Med Chem 2021;213:113191. [PMID: 33493828 DOI: 10.1016/j.ejmech.2021.113191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gecse KB, Lakatos PL. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects. Drugs 2016;76:1413-20. [DOI: 10.1007/s40265-016-0638-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
52 McKoy JM, Giles FJ. Biosimilars: Are They Really Safe? Cancer Treat Res 2019;171:61-73. [PMID: 30552657 DOI: 10.1007/978-3-319-43896-2_5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Ingrasciotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Drug Saf 2018;41:1013-22. [PMID: 29796832 DOI: 10.1007/s40264-018-0684-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
54 Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, Kvien TK, Smolen J, Tanaka Y, Burmester GR. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82. [PMID: 26964144 DOI: 10.1136/annrheumdis-2016-209166] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 19.0] [Reference Citation Analysis]
55 Trotta F, Belleudi V, Fusco D, Amato L, Mecozzi A, Mayer F, Sansone M, Davoli M, Addis A. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open 2017;7:e011637. [PMID: 28283484 DOI: 10.1136/bmjopen-2016-011637] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
56 Tóthfalusi L, Endrényi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014;15 Suppl 1:S5-11. [PMID: 24832831 DOI: 10.1007/s10198-014-0589-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
57 Rocco P, Selletti S, Minghetti P. Biosimilar switching and related medical liability. Journal of Forensic and Legal Medicine 2018;55:93-4. [DOI: 10.1016/j.jflm.2018.02.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
58 Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. Biologicals 2016;44:257-66. [DOI: 10.1016/j.biologicals.2016.03.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 9.3] [Reference Citation Analysis]
59 de Mora F, Fauser BCJM. Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic. Reprod Biomed Online 2017;35:81-6. [PMID: 28462793 DOI: 10.1016/j.rbmo.2017.03.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]